$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells

2018-10-26

2021-09-30

2022-09-30

200

Study Overview

Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells

This study will analyze and evaluate the following items: 1. The safety of natural killer（NK） cells for treatment of subjects with solid tumors. Forty patients will be enrolled for each of the five cancers (in total 200 patients will be enrolled). 2. The effectiveness of natural killer（NK）cell therapy alone or with chemotherapy or targeted drugs. Subjects from 18 to 75 years of age who are diagnosed with a solid tumor including pancreatic cancer, lung cancer, breast cancer, ovarian cancer and colon cancer, and for whom standard treatments are not effective, may be eligible for this study. Participants undergo the following procedures: Peripheral blood will be collected from a vein of arm. Peripheral blood mononuclear cells（PBMC） will be isolated and purified for NK manufacturing. After 14~21 days cultivation, activated NK will be harvested and formulated for clinical administration. Subjects will receive NK cell treatment by intravenous infusion. The frequency is once every 3 or 4 weeks for the first 3 months. Participants who respond well after 3 months may be eligible to continue NK cell therapy; and those not may receive NK therapy combined with chemotherapy and/or targeted drugs, or chemotherapy/targeted drugs alone. Evaluations during therapy including: 1. Clinical assessment, and history of medications; 2. Blood draws for routine and research tests, including but not limited to: lymphocyte population and circulating tumor cell analysis in peripheral blood; 3. CT scan, bone scan and positron emission tomography（PET ）scan, if indicated, for disease evaluation; 4. Pharmacokinetics study after NK infusion. For this test, the number of NK cells in the blood is measured over time at indicated time-points.

N/A

  • Lung Cancer
  • Breast Cancer
  • Colon Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • BIOLOGICAL: Activated NK
  • XuanWuH-NK

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2018-08-03  

N/A  

2019-01-09  

2018-08-14  

N/A  

2019-01-11  

2018-08-16  

N/A  

2019-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: NK cells

Activated NK from peripheral blood and/or umbilical cord blood（UCB）

BIOLOGICAL: Activated NK

  • Cell suspension
Primary Outcome MeasuresMeasure DescriptionTime Frame
Incidence of toxicity induced by NK infusionThe incidence of toxicity within each infusion within 6 months after NK administration6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Objective-response rate (ORR)Objective-response rate (ORR): defined as the proportion of patients who achieve partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at any time on study.6 months after 6 infusions of NK administration
Persistence of NKDuration of NK persistence: defined as duration from Day 1 to the time when the NK level goes back to stable levelDay 0, Day 7, Day30, Day 60, Day 90, Day 180

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Zhiguo Chen, PhD

Phone Number: 86-10-83198889

Email: chenzhiguo@gmail.com

Study Contact Backup

Name: Yu Zhao, PhD

Phone Number: 86-10-83198274

Email:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Age from 18 to 75 years (including boundary values); 2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon; 3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational); 4. Life expectancy > 6 months, and performance status（KPS）> 60 points; 5. Organ functions meet the following criteria:
    1. Blood bilirubin < 2mg/dL, 2. Aspartate transaminase（AST）<100 IU/L, 3. Alanine transaminase（ALT） <100 IU/L, 4. Creatinine <1.5 mg/dL, 5. Urea nitrogen ≤ 25 mg/dL, 6. Hemoglobin ≥ 9.0 g/dL, 7. White blood cell count>3.5×109/L, 8. Neutrophil count >1.5x109/L, 9. Platelet count > 80 × 109 /L, 10. Hematocrit >0.20, 6. No severe infections.
    Exclusion Criteria:
    1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids); 2. Patients who take chemotherapy within 1 month prior to treatment; 3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment; 4. Patients with T lymphoma and NK cell lymphoma; 5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.; 6. Seriously uncontrollable infected patients; 7. Patients who are allergic to the biological agents in this treatment; 8. Patients with organ transplantation or organ failure; 9. Subjects with severe cardiovascular disease and severe renal failure; 10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation; 11. Patients with active infection or fever; 12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction; 13. Subjects with pregnancy or during the lactating period.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • STUDY_DIRECTOR: Zhiguo Chen, PhD, Xuanwu Hospital, Beijing

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate